Update on breast cancer prevention

ONCOLOGY

Volumn 17, Issue 6, 2003, Pages 799-805

  Rastogi, Priya ^a   Vogel, Victor G ^a,b  

^a Hematology and Oncology ^*  (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ENZYME INHIBITOR; TAMOXIFEN;

BREAST TUMOR; CANCER INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TAMOXIFEN;

EID: 0042853136     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Vogel VG: Follow-up of the breast cancer prevention efforts. Clin Cancer Res 7(suppl 12):4413s-4418s, 2001.
2. Vogel VG: Chemoprevention: Reducing breast cancer risk, in Vogel VG (ed): Management of Patients at High Risk for Breast Cancer, pp 201-227. Maiden, Mass, Blackwell Science, Inc, 2001.
3. Powles TJ: Breast cancer prevention. The Oncologist 7:60-64, 2002.
4. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 90:1371-1388, 1998.
5. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989.
6. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93-97, 1998.
7. Veronesi U, Maisonneuve P, Sacchini V, et al: Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122-1124, 2002.
8. Veronesi U, Maisonneuve P, Rotmensz N, et al: Italian randomized trial among women with hysterectomy: Tamoxifen and hormone- dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160-165, 2003.
9. Vogel VG, Lo S: Preventing hormone- dependent breast cancer in high-risk women. J Natl Cancer Inst 95:91-93, 2003.
10. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998.
11. Powles TJ: The Royal Marsden Hospital (RMH) trial: Key points and rquestions. Ann N Y Acad Sci 949:109-112, 2001.
12. ll Chlebowski RT, Col N, Winer EP, et al: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328-3343, 2002.
13. Cuztck I, Powles T, Veronesi U, et al: Overview of the main outcomes in breast- cancer prevention trials. Lancet 361:296-300, 2003.
14. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial Lancet 360:817-823, 2002.
15. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281: 2189-2197, 1999.
16. Cauley JA, Norton L, Lippman ME, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125-134, 2001.
17. Costantino JP, Vogel VG: Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: An alternative view. Clin Breast Cancer 2:41-46, 2001.
18. KinsingerLS, Harris R.Woolf SILetal: Chemoprevention of breast cancer: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:59-69, 2002.
19. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999.
20. Vogel VG, Costantino JP, Wickerham DL, et al: The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 3:153-159, 2002.
21. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastro- zole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
22. Cuzick J: Update on new studies in Europe (abstract 20). Eur J Cancer 38:S44, 2002.
23. Fisher B: National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial: A reflective commentary. J Clin Oncol 17:1632-1639, 1999.
24. Wolmark N, Dunn BK: The role of tamoxifen in breast cancer prevention: Issues sparked by the NSABP Breast Cancer Prevention Trial (P-l). Ann N YAcadSci 949:99-108, 2001.
25. Vogel VG, Bevers T (eds): Handbook of Breast Cancer Risk Assessment:. Evidence- Based Guidelines for Evaluation, Prevention, Counseling, and Management. Boston; Jones and Bartlett Publishers, 2003.